On August 10, 2021, the Food and Drug Administration approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Association for Clinical Oncology (ASCO) commends the Biden Administration for proposing to rescind the Most Favored Nation (MFN) model from consideration. ASCO has consistently opposed the ill-advised MFN model, as it would have had a devastating impact on people with cancer.
The Centers for Medicare & Medicare Services (CMS) has released Merit-based Incentive Payment System (MIPS) performance feedback and final scores for performance year 2020 and associated MIPS payment adjustment information for payment year 2022.
The Centers for Medicare & Medicaid Services (CMS) released updates to the Inpatient Prospective Payment System (IPPS) for fiscal year (FY) 2022 final rule, including updates to Medicare payment policies and payment rates for most acute care hospitals.
The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work towards combating, and ultimately curing, diseases like cancer.
The American Society of Clinical Oncology (ASCO) recently published “Telehealth in Oncology: ASCO Standards and Practice Recommendations” in JCO Oncology Practice. The document provides oncology-specific standards for using telehealth to treat individuals with cancer.
The Association for Clinical Oncology submitted comments to the CMS regarding provisions in a 2022 Notice of Benefit and Payment Parameters proposed rule on extended and special enrollment provisions for federally-facilitated health insurance exchanges and state-based exchanges on the federal platform.
On July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
With COVID-19 case counts rising amid the spread of the Delta variant, the Association for Clinical Oncology joined more than 50 health care professional societies and organizations that represent millions of workers throughout health and long-term care in calling for all health care employers to require their employees to be vaccinated against COVID-19.
On July 21, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
The Association for Clinical Oncology (ASCO) along with other health care organizations sent a letter to U.S. Senate leadership to convey their opposition to an extension of mandatory Medicare sequestration as a pay-for in any infrastructure package. The letter urges lawmakers to reconsider the potential use of Medicare funds included in the bipartisan infrastructure framework.
Members of Congress recently reintroduced the Cancer Drug Parity Act (H.R. 4385) in the U.S. House of Representatives. The bill would ensure patient cost sharing for oral and other self-administered anticancer drugs is no less favorable than for traditional intravenous (IV) medication administered in an office setting.
The Centers for Medicare & Medicaid Services (CMS) released its 2022 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Specific provisions that would impact the cancer care community are included here.
ASCO provided comments on a recently released 21st Century Cures 2.0 Act discussion draft and accompanying Advanced Research Projects Agency Health (ARPA-H) request for information (RFI).
On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.